|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 21, 2016 ) The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Constipation (IBS-C) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with constipation (IBS-C) drugs market was valued at USD 1,045 Mn in 2015, and is expected to reach USD 1,597.5 Mn by 2022, expanding at a CAGR of 6.3% from 2016 to 2022.
Browse the full report Irritable Bowel Syndrome with Constipation (IBS-C) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-with-constipation-drugs-market
Market Insights
The global IBS-C drugs market is expected to progress at a CAGR of 6.3% during the forecast period. Europe is expected to be the largest regional market for IBS-C drugs followed by North America and Asia Pacific. Gradual growth in physician and patient awareness corresponding to the perpetual growth in disease prevalence are the major growth contributors to the global IBS-C market.
The global IBS-C drugs market is expected to witness significant growth over the forecast period due to significant adoption of IBS drugs. The recent FDA approvals and currently successful clinical trials of IBS drugs will further surge the market. Growing geriatric population and rise in healthcare expenditure are further creating huge scope for IBS-C drugs market. IBS-C is much prevalent in developed world, where dietary habits, work conditions, and similar such factors contribute to higher risk of lifestyle-related gastrointestinal diseases.
For More Reports To similar category @ http://www.credenceresearch.com/industry/pharmaceuticals-market
Among the regional markets, Europe is expected to lead the global market in terms of revenue share, expected to reach USD 639 Mn in 2022. Asia Pacific is the most emerging market and is expected to contribute significantly during the forecast period and will undergo progress corresponding to the global trends. The major players in the global IBS-C market include Sucampo AG, Activis, Cardinal Health, Catelent Pharma Solutions, Synergy Pharmaceuticals and others. Rapid commercialization, strong R&D activities, market consolidation strategies brought up by these players will be the major progressive features of the market. Introduction of highly targeted, orally administered peripherally acting mu-opioid receptor antagonist (PAMORA) therapies has also been a key market event.
Drugs such as lubiprostone, methylnaltrexone ad others are widely used for treating IBS-C in North America., thus addressing symptoms such as stomach pain or cramps, bloating, and infrequent or difficult passage of stool. Adoption of these drugs is further higher among elderly population.
Though rare, some probable side effects of these drugs include nausea, further stomach pain, swelling on face, tightness in throat, and others. Majority of IBS-C drugs are widely accepted and the rise in FDA approvals to newer drugs are adding up to create further market opportunities. As a result, several market players are increasingly focusing on research and development activities to come with better and novel pharmaceutical solutions for treating IBS-C.
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Blog: http://www.pdfdevices.com/lubiprostone-to-lead-the-global-irritable-bowel-syndrome-with-constipation-market-at-a-cagr-of-6-8-during-2016-2022/
Media Contact
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
Crednce Research
Chris Smith
1-800-361-8290
sales@credenceresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
